Board of Directors
Gergely Tóth, Ph.D., M.B.A.
Founder, Chief Executive Officer
Dr Gergely Tóth founded Gardedam Therapeutics in Palo Alto, CA in 2009 and is CEO of Cantabio Pharmaceuticals. Dr. Tóth is also affiliated with the Wolfson Brain Imaging Centre at University of Cambridge (UK) and with the Research Center for Natural Sciences at the Hungarian Academy of Sciences (Hungary) as the Head of the Research Group for Neurodegenerative Disease Drug Discovery. He is a scientist and a serial entrepreneur with a long-term focus on developing therapeutics for neurodegenerative diseases. He holds a Ph.D. from the Department of Biomedical Sciences at Creighton University (U.S.) in 2001, and an Executive M.B.A. in 2012 from the Judge Business School at the University of Cambridge (UK). He was a post-doctoral fellow at the Department of Molecular Biology at the University of California at Berkeley (U.S.). Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S., where he mostly pursued drug discovery research for Parkinson’s disease and Alzheimer’s disease.
Simon Peace, M.Sc., M.B.A., A.C.M.A.
Chief Financial Officer
Simon Peace is the Chief Financial Officer of Cantabio Pharmaceuticals. Mr. Peace is a qualified accountant with extensive experience in medical technology and life sciences. In addition to holding CFO appointments in various small companies, he has accumulated extensive global business experience at SmithKline Beecham, Cable & Wireless, GE Capital and GE Healthcare. Most recently, Mr. Peace spent seven years practicing M&A in med-tech and life sciences at GE Healthcare, which saw him buying and selling businesses and setting up joint ventures across Europe, U.S., Russia and the Middle East. Mr. Peace is qualified to the Chartered Institute of Management Accountants and holds a B.Sc. in Natural Sciences from the University of Durham, an M.Sc. in Manufacturing Management from the University of Bradford and an Executive M.B.A. from the University of Cambridge Judge Business School. He is also a member of the Finance and Tax Advisory Committee of the BioIndustry Association.
Thomas Sawyer, Ph.D., M.B.A.
Chief Operations Officer
Dr. Thomas Sawyer is the Chief Operations Officer of Cantabio Pharmaceuticals, combining a background in academic research with 13 years of experience in entrepreneurship, consulting and private equity investment in sectors including biotechnology, IT, logistics and natural resources across the globe. He has worked on M&A activities for private and public companies in the U.S., Europe and Africa and has experience in raising capital, IPOs, mergers and in CEO/CTO roles for start-up and private equity backed ventures. Dr. Sawyer holds a Ph.D. in Life Sciences from the University of Glasgow, an Executive M.B.A. from the University of Cambridge and is a visiting lecturer on Corporate Finance at the University of Exeter. Dr. Sawyer combines a strong technical background with business development, corporate finance and operations, and is an active mentor on the Accelerate Cambridge business accelerator program at the University of Cambridge.
Max Zhu, Ph.D.
Dr. Max Zhu has been a research scientist and Head of Computer-Aided Drug Design at Cantabio Pharmaceuticals Inc. since 2015. His areas of responsibility expanded in late 2017 to include business development activities for the company in Asia. Dr. Zhu has been a key player in the advancement of Cantabio's therapeutic programs. More recently he has become more involved in developing business and investor relationships for the company in Asia, where he is able to bring his network of contacts both in research and the investment community to help with the commercial development of the company. Prior to working with Cantabio, Dr. Zhu has worked as a scientist at VITA-Genes and also as Technology Officer at Vitargent Biotechnologies, both biotech companies based in the Hong Kong Science Park. In these roles he developed knowledge and knowhow in biomedical innovations and R&D commercialization in the region. At both companies he was also involved in business development and strategies as well as sales and marketing, gaining experiences as a biotech entrepreneur in the greater China area.
Dr. Zhu obtained his PhD at the University of Cambridge researching Alzheimer's Disease in 2013. His thesis focused on computational studies of the Abeta peptide and amyloid which led to the discovery of a set of compounds which could become potential drug leads for Alzheimer's disease. Dr. Zhu's research required the use of computer science, AI, genome and protein structure analysis, computational biology and chemistry, applying the combination of different skillsets and knowledge in a multi-disciplinary biomedical research environment, and he has been both lead and co-author on a number of peer reviewed articles in this area.